Cancer Science & Research
Open Access
ISSN: 2639-8478
Research Article
View / Download PDF
Vigil: Personalized Immunotherapy Generating Systemic Cytotoxic T Cell Response
Authors: James Herron, Noel Smith, Laura Stanbery, Phylicia Aaron, Luisa Manning, Ernest Bognar, Gladice Wallraven, Staci Horvath, John Nemunaitis.
Abstract
Recent research has focused on ways to activate and sustain an immune response. Vigil, an autologous tumor vaccine has shown both safety and efficacy in solid tumors. Here we show that advanced cancer patients exhibit reduced CD3+ T cells compared to healthy donor controls. Following vaccination with Vigil, the number of CD3+and CD3+CD8+ T cells increases to levels comparable to healthy controls. This data is suggestive that Vigil is able to generate a systemic cytotoxic T lymphocyte response.
Citation:
James Herron, Noel Smith, Laura Stanbery, et al. Vigil: Personalized Immunotherapy Generating Systemic Cytotoxic T Cell Response. 2020; 3(4).
DOI:
10.33425/2639-8478.1055
Editor-in-Chief
Lee Guek Eng
Department of Medical Oncology | National University of Singapore
View full editorial board →
Journal Metrics
Impact Factor
2.4*
Acceptance Rate
75%
Time to first decision
6-10 Days
Submission to acceptance
12-15 Days